RecruitingPhase 3NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Sponsor: Taiho Oncology, Inc.
Arlington, VA · Fairfax, VA · Manassas, VA · +27 more sites